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ABSTRACT
Objective: Psoriasis of early onset (type I; age of onset
(40 years) is associated with HLA-Cw*06 while the
shared epitope (SE) is associated with rheumatoid
arthritis susceptibility. Our aim was to investigate the role
of HLA-Cw*06 and HLA-DRB1 genes (including SE) with
psoriatic arthritis (PsA) susceptibility.
Methods: In a case–control association study, HLA-
Cw*06 phenotype frequencies were compared between
patients with PsA (n=480), psoriasis alone (n=611)
and healthy controls (n=166). Similarly, at the HLA-
DRB1 locus, phenotype and SE frequencies were
compared in patients with PsA (n=480), early undiffer-
entiated inflammatory arthritis alone (n=1621) and
healthy controls (n=537).
Results: The HLA-Cw*06 phenotype was associated with
type I psoriasis (OR 6.9, 95% CI 4.4, 11.1,
p=2.2610
221) and with patients with PsA having type I
psoriasis (OR 5.0, 95% CI 3.2, 7.9, p=4.39610
213), but
not with patients with PsA having type II psoriasis (age of
onset .40 years). HLA-DRB1*07, in linkage disequili-
brium with HLA-Cw*06, was also associated with patients
with PsA having type I psoriasis (OR 2.7, 95% CI 2.1, 3.7,
p,0.00001). HLA-DRB1*04 alleles and the SE were
associated with undifferentiated inflammatory arthritis but
not with PsA.
Conclusions: The SE is not a PsA susceptibility locus.
HLA-Cw*06 and HLA-DRB1*07 are associated with
patients with PsA having type I psoriasis, suggesting that
the primary association is with age of onset of psoriasis.
Patients with PsA having type I psoriasis, therefore, have
a genetic background different to those with type II
psoriasis, and adjustment for this is necessary in future
studies that investigate the genetic susceptibility of PsA.
Psoriatic arthritis (PsA) is commonly defined as ‘‘an
inflammatory arthritis (IA) associated with psor-
iasis, which is usually negative for rheumatoid
factor (RF)’’.
1 A strong genetic component to
susceptibility is suggested by the sibling recurrence
risk ratio (ls), which is estimated to be 27.
23Part
of the genetic predisposition is likely to be
explained by genes within the major histocompat-
ibility complex (MHC) region. For example,
human leucocyte antigen (HLA) associations with
psoriasis and IA in the form of rheumatoid arthritis
(RA) are well characterised and, in each case, the
MHC genes involved are recognised as the major
disease susceptibility locus. Psoriasis has two
distinct ages of onset: type I, early onset disease
occurring at (40 years of age and type II, late
onset occurring at .40 years of age. Carriage of the
HLA class I allele, HLA-Cw*06 is associated with
type I but not type II psoriasis.
4–13 In contrast, RA
is associated with carriage of the shared epitope
(SE) of the HLA class II DRB1 gene (a group of
DRB1 alleles sharing a conserved amino acid motif
in the third hypervariable region of the DRb
chain).
14 HLA-Cw*06 is not found on haplotypes
encoding the SE.
For PsA disease susceptibility, separating the
HLA-related genetic contribution from the con-
tribution to psoriasis and IA alone is a challenge.
There is evidence to suggest that carriage of the
HLA-Cw*06 allele is associated with patients with
PsA with type I psoriasis.
12 15–19 Studies of the HLA
class II DRB1 gene have reported that the HLA-
DRB1*07 phenotype is associated with peripheral
arthritis in PsA while HLA-DRB1*04 is associated
with a subgroup of patients with PsA with
polyarthritis mimicking that of RA.
20–26 In one
study of the HLA-DRB1 locus, HLA-DRB1*0402
(which is not a SE allele) was found to occur more
frequently in patients with PsA compared with RA
or healthy controls, whereas HLA-DRB*0401
(which is a SE allele) occurred less frequently.
27
Conflicting results have been reported with regard
to the HLA-DRB1*02 (HLA-DRB*15 or HLA-
DRB*16) and PsA susceptibility with a decrease
found in a UK study, but not in a cohort from
Toronto.
28 29 More recently, a UK study showed no
overall difference in the frequency of the SE
between PsA cases and controls.
28
Of the associations reported, however, it is still
unclear whether the primary association is with
PsA itself or secondary to one of the two
constituent components, ie, IA or psoriasis. In
previous studies, all appropriate comparison groups
have not been analysed and some studies have also
lacked power to address this question. The aim of
this study was to compare the association between
HLA-Cw*06 and HLA-DRB1, including the SE, with
PsA susceptibility by comparing these phenotypes
in patients with PsA, early undifferentiated
inflammatory arthritis (UIA) alone, psoriasis alone
and healthy controls.
METHODS
Overview
For this study, we did not investigate HLA-Cw*06
carriage in UIA patients or HLA-DRB1 allele
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excluded a role for these genes in the respective conditions.
12 30–33
A case–control association study was performed to investigate
the role of HLA-Cw*06 in determining susceptibility to PsA by
comparing allele and phenotype frequencies between patients
with PsA, psoriasis alone and healthy controls. For the HLA-
DRB1 gene variants, HLA-DRB1*04, HLA-DRB1*07, HLA-
DRB1*02 (HLA-DRB*15 or HLA-DRB*16) and SE phenotype
frequencies were compared in patients with PsA, UIA alone and
healthy controls. Stratification analyses were performed by
subdividing patients with PsA into type I and type II psoriasis
according to the age at onset of their skin disease (type I=age
of onset (40 years and type II=.40 years of age). Analyses
were also repeated in subsets of patients with PsA stratified by
the presence of RF.
Subjects
Patients with psoriatic arthritis
The recruitment of patients with PsA for this study has been
described previously.
34 In brief, patients with PsA (n=480)
under active follow-up by hospital rheumatologists were
recruited from throughout the UK with the majority of them
coming from north-west England. All patients satisfied the
inclusion criteria of having both clinically documented inflam-
matory synovitis and psoriasis regardless of their RF status. A
trained research nurse interviewed the patients and completed a
standardised clinical history and examination protocol. Detailed
demographic and clinical information were obtained and whole
blood was taken for the measurement of RF status, DNA
extraction and subsequent genetic analysis.
Patients with psoriasis
As described previously,
35 patients with type I psoriasis (age of
onset (40 years) (n=611) were recruited via the Dermatology
Centre at Hope Hospital in Manchester. Some of the patients
with psoriasis may have an IA, but this was not documented for
the majority. A subset (n=229) underwent an examination to
exclude inflammatory joint involvement.
Undifferentiated inflammatory arthritis
Patients with early UIA were recruited from the Norfolk
Arthritis Register (NOAR) as described previously.
36 This is a
primary-care-based inception cohort of subjects with primary
UIA. Patients were aged >16 years with two or more inflamed
peripheral joints lasting at least 4 weeks. For the purpose of this
study, all patients with HLA-DRB1 data available were included
(n=1621).
Population controls
Control subjects without a history of IA or psoriasis were
recruited from blood donors and general practice registers
(n=537).
All patients and controls were white Caucasians of British
descent. They were recruited with ethical committee approval
(MREC 99/8/84 (PsA samples); LREC 00089 (psoriasis samples),
LREC 2003-075 (NOAR samples)) and provided written
informed consent.
HLA typing
Both broad HLA genotyping (HLA-Cw and HLA-DR) and
subtyping to define SE alleles were performed using 50 ng of
genomic DNA amplified with the Dynal RELI SSO HLA-Cw
typing and HLA-DRB1 kits (http://www.dynalbiotech.com)
using a third of the specified volumes for the polymerase chain
reaction reagents in a 20 ml reaction instead of 60 ml as described
previously.
34 Alleles were assigned using the Pattern Matching
Program provided by Dynal (Invitrogen Ltd, Paisley, UK).
Statistical analysis
Allele and phenotype frequencies for HLA-Cw*06 were com-
pared between PsA cases, psoriasis cases and controls using the
x
2 test implemented in STATA 8.
For the HLA-DRB1gene, HLA-DRB1*04, HLA-DRB1*07, HLA-
DRB1*02 (HLA-DRB*15 or HLA-DRB*16) and SE phenotype
frequencies were compared between cases with PsA, UIA and
controls using the x
2 test implemented in STATA 8. The SE
was defined by the presence of any of the following alleles:
HLA-DRB1*0101, HLA-DRB1*0102, HLA-DRB1*0104, HLA-
DRB1*0401, HLA-DRB1*0404, HLA-DRB1*0405, HLA-
DRB1*0408 and HLA-DRB1*1001.
The PsA cohort was divided into patients with type I and
type II psoriasis by their age at onset of their psoriasis
((40 years or .40 years, respectively) and the analyses were
repeated for each subset of PsA. Similar analysis was undertaken
after stratifying the PsA cohort by their RF status.
Linkage disequilibrium analysis
Pairwise linkage disequilibrium (LD) measures (both D9 and r
2)
were investigated between HLA-Cw*06 and HLA-DRB1*07 using
HelixTree (Golden Helix Inc, Bozenian, MT, USA). These data
has been reported previously.
34
RESULTS
A summary of the samples used for the HLA-Cw*06 and HLA-
DRB1 analysis is provided in table 1.
Patient characteristics
Psoriatic arthritis
The characteristics of the PsA cohort have been described
previously.
34 There was an almost equal gender distribution
with 57% being female and 74% having type I psoriasis. The
median duration of psoriasis was 19 years (interquartile range
(IQR) 9–33) and the median duration of joint disease was
10 years (IQR 5–19). A majority (63%) developed psoriasis
before the onset of joint disease. RF was present in 17% (titre
.1:40), 81% had nail involvement, 57% had five or more
damaged joints (polyarthritis subgroup) and the median HAQ
score was 1.25. As shown previously, patients with PsA with
type I psoriasis have a stronger family history of both skin and
joint disease and tend to develop arthritis after the onset
of psoriasis.
19 37 In addition, patients with PsA with type I
psoriasis had a longer duration of joint disease and more nail
Table 1 Number of subjects in study (where data are available)
Subjects
HLA-Cw*06
information: n
HLA-DRB1
information: n
PsA whole cohort 453 465
PsA with type I psoriasis 335 342
PsA with type II psoriasis 115 120
Psoriasis (all type I) 611 NA
UIA NA 1621
Population controls 166 537
UIA, early undifferentiated inflammatory arthritis; PsA, psoriatic arthritis; NA, not
available.
For three PsA cases, data were not available as to the type of psoriasis present.
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joints compared with those with type II psoriasis.
Psoriasis
All patients had type I psoriasis with 46% (283 of 611) being
female. The median age of onset of psoriasis was 19 years (IQR
13–27). Some of these patients may have an unrecognised IA,
but a subset (n=229) have been specifically examined by a
dermatologist to exclude an IA. All 611 patients with psoriasis
were included in the analysis. No significant differences in
clinical, demographic or HLA-Cw*06 carriage data were observed
between those patients with psoriasis in whom PsA had been
specifically excluded and those where it had not (HLA-Cw*06
carriage was 43% in those without PsA versus 40% in the
remainder, p=0.44).
Early undifferentiated inflammatory arthritis
Within the UIA cohort, 1053 (65%) were female. At baseline,
the median disease duration was 6 months (IQR 3–12); RF was
present at a titre .1:40 in 452/1433 (31.5%) and 743 (48.3%)
satisfied the American College of Rheumatology criteria for
RA.
38 By year 5, 11% of the patients were recorded to have
psoriasis in addition to their IA and by year 10 of follow-up,
12% developed psoriasis.
Controls
In the population control cohort, gender information was
available for 268 subjects of whom 119 (44%) were female. HLA-
Cw*06 data were available for 166, while HLA-DRB1 data were
available for 573 subjects.
HLA-Cw*06
The frequency of the HLA-Cw*06 phenotype in the population
controls tested in the current study was within the range
reported previously
15 16 25 26 39–41 (table 2).
When compared with controls, the HLA-Cw*06 phenotype
was shown to be strongly associated with PsA (odds ratio (OR)
3.6, 95% CI 2.3, 5.8 and p=5.5610
29) (table 2 and fig 1).
Stratification analysis in the PsA cohort by RF status made no
difference to the result (OR in the RF-negative PsA subgroup
3.6, 95% CI 2.3, 5.9, p=9.6610
29). However, the association
with HLA-Cw*06 was confined to the subgroup of patients with
PsA with type I psoriasis (OR 5.0, 95% CI 3.2, 7.9,
p=4.39610
213) and was not observed in patients with PsA
with type II psoriasis (OR 1.1, 95% CI 0.6, 2.1, p=0.76).
For the psoriasis cohort, as expected, HLA-Cw*06 was
strongly associated with type I psoriasis compared with controls
(OR 6.9 95% CI 4.4 to 11.1, p=2.15610
221) (table 2 and fig 1).
To determine whether HLA-Cw*06 is associated with PsA itself
or primarily with psoriasis, we compared the HLA-Cw*06
phenotype frequencies in those patients with PsA with type I
psoriasis and patients with type I psoriasis alone. A much
weaker association was noted (PsA with type I psoriasis versus
type I psoriasis, OR 0.72, 95% CI 0.55, 0.96, p=0.02),
suggesting that the primary association of HLA-Cw*06 is with
type I psoriasis and not PsA per se.
HLA-DRB1
Stratification analysis showed that the HLA-DRB1*07 pheno-
type was strongly associated in those patients with PsA with
type I psoriasis (OR 2.7, 95% CI 2.1, 3.7 and p,0.00001)
compared with controls. Although, HLA-DRB1*07 occurred
significantly more frequently in PsA cases than controls, we
have previously reported that this allele exhibits considerable
LD with HLA-Cw*06 (correlation (r
2)=0.46).
34 Therefore, it was
not unexpected that, after adjusting for the presence of HLA-
Cw*06 phenotype, the association of HLA-DRB1*07 with PsA as
a whole group (OR 1.38, 95% CI 0.88, 2.17, p=0.16) or in the
subgroup with type I psoriasis compared with controls (OR
1.63, 95% CI 0.96, 2.78, p=0.07) was no longer statistically
significant. However, the association of PsA with HLA-Cw*06
remained similar after adjusting for the presence of the HLA-
DRB1*07 (OR 3.2, 95% CI 2.0 to 5.3), confirming that the
primary association is with HLA-Cw*06 and not HLA-DRB1*07.
Patients with PsA negative for RF were less likely to carry the
HLA-DRB1*04 phenotype compared with population controls
(OR 0.74, 95% CI 0.55, 0.99, p=0.03), but no difference was
observed between those patients with PsA with a positive RF
compared with controls (OR 0.96, 95% CI 0.56, 1.61, p=0.88).
In addition, the HLA-DRB1*04 phenotype occurred less fre-
quently in patients with PsA with type I psoriasis compared
with population controls (p=0.004), but no difference was
observed in those patients with PsA with type II psoriasis
compared with controls (p=0.45). Within patients with PsA,
when the HLA-DRB1*04 phenotype was present, it occurred
more commonly in patients with PsA with type II psoriasis
compared with those with type I psoriasis (OR 1.81, 95% CI
1.14, 2.86, p=0.007). No association was detected with those
patients with PsA having >5 damaged (poly-damaged) or >5
involved (poly-involved) joints with the HLA-DRB1*04 pheno-
type compared with population controls (OR 0.87, 95% CI 0.6,
1.2, p=0.39 and OR 0.81, 95% CI 0.60, 1.08, p=0.14,
respectively).
Table 3 shows that in the UIA cohort, the HLA-DRB1*04
phenotype was more common than population controls (OR
1.40, 95% CI 1.14, 1.72 and p=0.001), while the HLA-DRB1*07
phenotype was more common in the PsA cohort compared with
population controls (OR 2.15, 95% CI 1.62, 2.84, p=2.6610
28).
However, when comparing patients with PsA with type II
psoriasis with UIA subjects, no difference was observed
between these two cohorts for either the HLA-DRB1*04 or the
HLA-DRB1*07 phenotypes (p=0.35 and p=0.45 respectively).
When compared with patients with PsA with type I psoriasis,
the frequency of the HLA-DRB1*04 phenotype was significantly
higher in UIA subjects (OR 2.17, 95% CI 1.66, 2.84, p,0.0001).
Conversely, the HLA-DRB1*07 phenotype was significantly
higher in patients with PsA with type I psoriasis compared
with UIA (OR 3.23, 95% CI 2.51, 4.14, p,0.0001).
Table 2 Comparison of HLA-Cw*06 in PsA cases, psoriasis and
controls
HLA-Cw*06
PsA cases
Population
controls
n=166
Type I
psoriasis
n=611
Total cohort
n=453
Type I
n=335
Type II
n=115
0 262 (57.8) 166 (49.6) 94 (81.7) 138 (83.1) 254 (41.6)
1 182 (40.2) 162 (48.4) 19 (16.5) 28 (16.9) 323 (52.9)
2 9 (2) 7 (2) 2 (1.8) 0 34 (5.5)
Phenotype 191 (42.2) 169 (50.4) 21 (18.3) 28 (16.9) 357 (58.4)
p-Value* 5.5610
29 4.39610
213 0.76 2.15610
221
PsA, psoriatic arthritis. Type I, patients with PsA with type I psoriasis; type II, patients
with PsA with type II psoriasis.
*Comparison of phenotype (carriage of one or two alleles) with population controls
using the x
2 test.
Data shown in n (%). Data were not available for three patients as to the type of
psoriasis present.
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to the HLA-DRB1*02 (HLA-DRB*15 or HLA-DRB*16) and PsA
susceptibility with a decrease found in a UK study, but not in a
cohort from Toronto.
28 29 We did not observe a difference in our
cohort.
Shared epitope
When comparing patients with PsA and controls, no association
was detected with SE allele carriage and PsA (table 4 and fig 2)
either in the entire cohort (p=0.94) or after stratifying the
patients with PsA by type I or type II psoriasis or by their RF
status. For example, no association was detected when comparing
SE phenotype between patients with PsA with type I psoriasis
and population controls (OR 0.90, 95% CI 0.68, 1.19, p=0.43) or
when comparing patients with PsA with type II psoriasis with
population controls (OR of 1.24, 95% CI 0.82, 1.88, p=0.28).
As expected, the SE was significantly associated with UIA
compared with controls (OR 1.88, 95% CI 1.53, 2.29,
p=3.63610
210; table 4 and fig 2). When comparing the UIA
and PsA subgroups directly, the frequency of the SE phenotype
was significantly higher in UIA subjects compared with those
patients with PsA with type I psoriasis (OR 2.08, 95% CI 1.64,
2.66, p=7.1610
210), but the effect size was lower when
comparing UIA subjects to patients with PsA with type II
psoriasis (OR 1.51, 95% CI 1.02, 2.22, p=0.03).
DISCUSSION
In this large association study of patients with PsA, we have
shown that both HLA-Cw*06 and HLA-DRB1*07 are associated
with PsA susceptibility in the subgroup of patients with PsA
with type I psoriasis but not in those with type II psoriasis,
suggesting that the primary association is with type I psoriasis.
Our data also confirms that the association with the HLA-
DRB1*07 is because this allele is in LD with HLA-Cw*06. We can
find no evidence for association of the SE with PsA suscept-
ibility.
The simultaneous investigation of two HLA genes in large
cohorts of patients with PsA and appropriate control groups has
enabled us to try and dissect out the contribution to PsA over
and above that to UIA alone and psoriasis alone. We did not
investigate HLA-Cw*06 in UIA patients or HLA-DRB1 in
patients with psoriasis as previous studies have excluded a role
for these genes in the respective conditions.
12 30–33 Previous
studies on patients with psoriasis have shown that both HLA-
Cw*06 and HLA-DRB1*07 are associated with type I psoriasis,
but not with type II psoriasis.
12 30 31 42 We have confirmed that,
although both phenotypes show association, the HLA-DRB1*07
result has arisen due to LD with HLA-Cw*06. Furthermore,
analysis of HLA-Cw*06 phenotype in patients with type I
psoriasis, patients with PsA (stratified according to their types
of psoriasis) as well as population controls has allowed us to
conclude that the association is primarily with type I psoriasis
rather than PsA itself.
Unsurprisingly, HLA-DRB1*04 was found to occur more
frequently in the UIA cohort, the majority of whom satisfied
American College of Rheumatology classification criteria for RA
by 5 years. In contrast, it occurred less commonly in those
patients with PsA who were negative for RF and those patients
with PsA with type I psoriasis compared with controls. When
HLA-DRB1*04 was present in patients with PsA, it occurred
more frequently in those with type II psoriasis compared with
patients with PsA with type I psoriasis. This may suggest that
the HLA-DRB1*04 allele is protective for type I PsA.
Alternatively, it may simply reflect the fact that if one allele
is increased in frequency (HLA-DR*07 allele frequency increased
in patients with PsA with type I psoriasis) then the frequency of
others must be reduced.
The broad inclusion criteria for PsA used in this study may
have led to the misclassification of some patients who have true
RA and coincidental psoriasis being classified as PsA. In this
situation, one may have expected to see an association with
HLA-DRB1*04 in either the RF-positive subgroup of patients
with PsA or those with polyarticular disease but we did not find
that to be the case. An advantage of not excluding RF-positive
patients is that we have been able to stratify the patients with
PsA by their RF status to explore whether RF is an important
co-factor in PsA susceptibility. However, in no situation did this
stratification change the conclusions of an analysis, suggesting
that it is not. Our genetic findings, therefore, accord with recent
clinical data suggesting that polyarticular PsA is more similar to
oligoarticular PsA than to RA.
43
We have also confirmed the finding of others that SE was not
associated with PsA susceptibility.
28 29 Unsurprisingly, SE was
Figure 1 Comparison of HLA-Cw*06 phenotype in psoriatic arthritis
(PsA) cases, psoriasis and controls. Odds ratios and 95% confidence
intervals are shown on a log scale.
Table 3 HLA-DRB1 phenotypes in PsA cases, UIA and controls (where data available)
HLA-DRB1
PsA cases
Controls
n=537
p value (PsA whole cohort
compared with controls)
UIA
n=1621
p Value (UIA compared
with controls)
Whole cohort
n=465
Type I
n=342
Type II
n=120
DRB1*02 118 (25) 81 (24) 36 (30) 145 (27) 0.57 342 (21) 0.006
DRB1*04 142 (31) 92 (27) 48 (40) 195 (36) 0.06 719 (44) 0.001
DRB1*07 188 (40) 159 (46) 29 (24) 129 (24) 3.09610
28 344 (21) 0.21
PsA, psoriatic arthritis; UIA, early undifferentiated inflammatory arthritis; type I, patients with PsA with type I psoriasis; type II, patients with PsA with type II psoriasis.
Data shown in n (%) unless stated otherwise.
Extended report
680 Ann Rheum Dis 2008;67:677–682. doi:10.1136/ard.2007.071399found to be strongly associated with UIA susceptibility and
occurred significantly more frequently in UIA subjects com-
pared with patients with PsA with type I psoriasis. The smaller
number of patients with PsA with type II psoriasis may have
limited the interpretation of this analysis but the odds of
carrying SE was also significantly higher in UIA subjects
compared with patients with PsA with type II psoriasis. The
findings confirm that, although patients with PsA with type II
psoriasis appear more genetically similar to UIA subjects than
do patients with PsA with type I psoriasis, UIA and patients
with PsA with type II psoriasis are sufficiently different, in
terms of their genetic susceptibility, to be viewed as distinct
entities.
In summary, our study confirms the established strong
association of HLA-Cw*06 with type I psoriasis susceptibility.
The association of PsA with HLA-Cw*06 is of similar strength
and is confined to those patients with PsA with type I psoriasis.
We conclude, therefore, that HLA-Cw*06 does not confer
additional susceptibility to IA in patients with psoriasis. We
also note that the association between HLA-DRB1*07 and PsA is
due to its significant LD with HLA-Cw*06. No independent
association was detected with HLA-DRB1*02, HLA-DRB1*04,
HLA-DRB1*07 or with the SE and PsA. Our study suggests that
the genetic susceptibility of PsA cannot be explained by the
HLA-Cw*06 or HLA-DRB1 loci and confirms the importance of
choosing the appropriate control populations when studying
this condition. The findings also suggest that adjustment for
HLA-Cw*06 is of central importance when attempting to dissect
the genetic susceptibility of IA in patients with psoriasis.
Finally, our findings suggest that patients with PsA with type I
and type II psoriasis have different genetic susceptibility factors
and that patients with PsA with type I psoriasis are more
genetically similar to type I patients with psoriasis at least at
the HLA-Cw*06 locus. This implies that in future genetic
studies, it may be important to stratify patients with PsA
according to the age of onset of psoriasis.
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